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Abstract
Background: Idiopathic pulmonary fibrosis is a chronic, progressive, and severe disease with a limited response to
currently available therapies. Epithelial cell injury and failure of appropriate healing or regeneration are central to
the pathogenesis of idiopathic pulmonary fibrosis. The purpose of this study is to investigate whether intratracheal
transplantation of alveolar type II-like cells differentiated from induced pluripotent stem cells can stop and reverse
the fibrotic process in an experimental model of bleomycin-induced lung fibrosis in rats.
Methods: Human induced pluripotent stem cells were differentiated to alveolar type II-like cells and characterized.
Lung fibrosis was induced in rats by a single intratracheal instillation of bleomycin. Animals were transplanted with
human induced pluripotent stem cells differentiated to alveolar type II-like cells at a dose of 3 × 106 cells/animal 15
days after endotracheal bleomycin instillation when the animal lungs were already fibrotic. Animals were sacrificed
21 days after the induction of lung fibrosis. Lung fibrosis was assessed by hydroxiprolin content, histologic studies,
and the expression of transforming growth factor-β and α-smooth muscle actin.
Results: Cell transplantation of alveolar type II-like cells differentiated from induced pluripotent stem cells can
significantly reduce pulmonary fibrosis and improve lung alveolar structure, once fibrosis has already formed. This is
associated with the inhibition of transforming growth factor-β and α-smooth muscle actin in the damaged rat lung
tissue.
Conclusion: To our knowledge, this is the first data to demonstrate that at the fibrotic stage of the disease,
intratracheal transplantation of human induced pluripotent differentiated to alveolar type II-like cells halts and
reverses fibrosis.
Keywords: Induced pluripotent stem cells, Alveolar type II cells, Cell differentiation, Idiopathic pulmonary fibrosis,
Cell therapy
One sentence summary
Transplantation of human iPSC-derived AEC2 reduces
lung fibrosis, associated with reduced expression of α-
SMA and TGF-β in the experimental bleomycin model
in rats.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, and severe disease of unknown cause with a limited
response to currently available therapies [1–3]. The me-
dian survival time is 3 to 5 years from the time of diag-
nosis [1]. Most patients show a progressive decline in
pulmonary function leading to respiratory failure and
death. The poor prognosis, combined with the scarcity
of treatment options, provides a strong rationale for de-
velopment of novel therapeutic alternatives for this dis-
ease [1].
Alveolar epithelial cell injury and failure of appropriate
healing or regeneration are central to the pathogenesis
of IPF. Epithelial cell damage and death result in breaks
in epithelial basement membranes of alveoli. Subsequent
migration of fibroblasts and myofibroblasts into the al-
veolar space through these gaps leads to intra-alveolar fi-
brosis with an exaggerated accumulation of extracellular
matrix (ECM) components. The resulting fibrosis dis-
turbs the normal lung architecture leading to lung dys-
function and respiratory failure [4–6].
Within the structure of the alveolar epithelium are the
alveolar type II (AEC2) and type I (AEC1). One of the
main important functions of AEC2 is the production, se-
cretion, and recycling of pulmonary surfactant proteins
that decrease the surface tension of the alveoli providing
efficient ventilation and alveolar stability as well as act-
ing as a protective barrier against possible infections [7,
8]. Under normal conditions, AEC2 have the ability of
self-renewal and are the progenitor cell type for AEC1,
the cells responsible for gas exchange in the alveoli [9,
10]. However, during the course of IPF, AEC2 undergo
cell death and are replaced by myofibroblasts that show
a great proliferative activity. In this regard, the death of
the AEC2 and activation of fibroblasts or myofibroblasts
are central in the development of the pulmonary fibrosis
[11].
The loss of AEC2 prevents renewal and repairing of
the alveolar wall and induces the secretion of fibrogenic
mediators such as transforming growth factor beta
(TGF-β). TGF-β acts as a major pro-fibrotic cytokine,
potently increasing fibroblast recruitment, proliferation,
differentiation into myofibroblasts, and production of
ECM [12]. Myofibroblasts compose the majority of cells
in the fibroblastic foci and are characterized by the pres-
ence of α-smooth muscle actin (α-SMA). They play an
important role in the pathogenesis of pulmonary fibrosis
by contributing to increased ECM deposition and re-
duced contractibility of lung tissue during IPF. Myofi-
broblasts also secrete TGF-β that in turn induces AEC2
apoptosis reducing the capability of wound healing and
increasing lung architecture damage [11].
Cell transplantation therapy to treat lung disease has
been proposed before; the most widely tested cell types
are bone marrow mesenchymal stromal cells [13], but
also other cell types such as cord blood mesenchymal
stem cells, human amnion epithelial cells (hAEC) [14],
and AEC2 in both animal and human clinical studies
[15–17]. AEC2 are responsible for repairing the dam-
aged alveolar epithelium in the event of lung damage
and consequently proposed as an optimal cell type for
the treatment of IPF. In preclinical studies, the adminis-
tration of AEC2 during the inflammatory phase or dur-
ing the fibrotic phase resulted in significant reduction of
fibrosis and the restoration of surfactant levels [15, 16].
Moreover, in a clinical study performed with IPF pa-
tients, the intratracheal administration of heterologous
AEC2 was safe, well tolerated, with no relevant side ef-
fects, stabilized disease progression, and improved
health-related quality of life throughout a 1-year clinical
follow-up [17]. Therefore, results of transplanting AEC2
have been promising in halting pulmonary fibrosis pro-
gression both in animals and in humans. Additionally,
other minor lung cell populations have also been de-
scribed as potential stem cells or distal epithelium that
are activated in particular situations such as acute injury
and are yet to be tested [18–20].
Induced pluripotent stem cells (iPSC) have been pro-
posed as an alternative source of cells for cell therapy to
treat lung disease with the possibility of increased cell
production for clinical applications [21]. Differentiation
of mouse or human iPSC to definitive endoderm and
then into distal AEC2 and proximal lung cells has been
well described before [22–25].
The aim of our study was to test in a rat model of
bleomycin (BLM)-induced lung fibrosis if transplant-
ation of iPSC-like AEC2 could improve the fibrotic
phenotype and reconstruction of alveolar structure. Dif-
ferentiation of iPSC resulted in high efficiency of surfac-
tant protein C (SP-C)-positive lung cells of
approximately 90–95%. The results demonstrate that
iPSC-AEC2 intratracheal transplantation after 15 days of
BLM instillation, when fibrosis had been fully developed,
led to decreased collagen deposition and a significant de-
crease in both TGF-β expression and α-SMA expression.
In summary, our results show a reduction in the severity
of pulmonary fibrosis with iPSC-like AEC2 intratracheal
transplantation at the fibrotic stage of development of
the disease.
Materials and methods
iPSC preparation and its differentiation to AEC2
Culture of induced pluripotent stem cells
Human iPSC were purchased from ThermoFisher and
cultured on vitronectin (ThermoFisher)-coated 6 well
plates in Essential 8™ Flex Medium (Gibco). Cells were
adapted to single cell passaging for 4–5 passages before
starting the differentiation protocol.
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Differentiation from iPSC to AEC2
The differentiation protocol from iPSC to AEC2 was
adapted from previously published protocols by the Kot-
ton group [24]. Single cell passaging-adapted iPSC were
plated on vitronectin (ThermoFisher)-coated plates at
400,000 cells/well in 12MW in Essential 8™ Flex
Medium with Rock inhibitor. Twenty-four hours later
(day 0), definitive endoderm was induced using STEM-
diff definitive endoderm kit (StemCells Technologies)
for 72 h (day 3). For the induction of anterior foregut
endoderm, the cells were replated on human placenta
collagen IV (Sigma)-coated 6MW at about 200,000
cells/cm2 in basal differentiation media (BDM) (DMEM:
F12 (3:1), 1 x B27, 0.5 x N2 (all from ThermoFisher), as-
corbic acid 25 μg/ml (Sigma)) plus SB431542 10 μM
(Merk) and Dorsomorphin 2 μM (Sigma) from day 3 to
day 6. Rock inhibitor was added at day 3 and removed at
day 4. For lung progenitor induction, the cells were
transferred to BDM plus fibroblast growth factor-10
(FGF10) 10 ng/ml, keratinocyte growth factor (KGF) 10
ng/ml, bone morphogenetic protein-4 (BMP4) 10 ng/ml
(all from Peprotech), retinoic acid 50 μM (Sigma), and
CHIR99021 3 μM (Merk) from day 6 to day 15. At day
8, the cells were split 1:5. For the last step of AEC2 in-
duction, the cells were transferred to BDM plus KGF 10
ng/ml and CHIR99021 3 μM from day 15 to day 22.
RNA extraction and cDNA synthesis for in vitro work
For RNA extraction, during the differentiation of iPSC
to AEC2, in each stage, cells were washed with PBS and
dissociated by adding trypsine solution or TrpLE™ select
(ThermoFisher Scientific) to the plate. Cells were col-
lected in a 15-ml tube and diluted with more medium,
and the suspension then was centrifuged 5 min at 800
rpm. The pellet obtained was used for RNA extraction.
RNA from cells was extracted following the PureLinkR
mini Kit (Ambion) protocol and was quantified measur-
ing the absorbance at 260 nm at Nanodrop ND-100
Spectrophotometer (Thermo Scientific). A 1% agarose
gel was made to confirm that there was no degradation
of RNA. The synthesis of cDNA was done using a kit
(Bioline) and XP Cycler. We synthesized 1 μg for sample
iPSC, definitive endoderm, day 15 and day 22. However,
for AEC2, we synthesized 360 μg.
Quantitative real-time PCR for in vitro work
RT-PCR was performed with SYBR Green: 7.5 μl SYBR
Green, 0.75 μl of each primer at 10 μM, 2 μl 10× PCR
buffer, and 500 ng of RNA in 8 μl of water. Duplicates
for each sample were performed in 96-well plates and
analyzed for all the markers (GAPDH, Oct4, NKX 2.1,
FOXA2, FOXA1, FOXP2, Sox9, SP-C, surfactant protein
A (SP-A), p63, GATA6, and Aquoporin5). For definitive
endoderm, we analyzed the following markers: CXCR4,
C-Kit, Sox17, MEF2C (mesoderm specific was used as a
negative control), and GAPDH. The real-time PCR reac-
tion was performed with the 7500 Real Time PCR Sys-
tem (10 min at 95 °C, 40 cycles 10 s at 95 °C, and finally
40 cycles 34 s at 60 °C). RT-PCR experiments were run
at Genetic Forensics Laboratory (Hospital Clinic, UB).
Fluorescence activated cell-sorting (FACS)
For flow cytometry, the samples were centrifuged 5 min
at 200g, and then resuspended in PBS 5% Donkey
serum-0.5% Triton X-100 and incubated 15min at room
temperature. After that, the samples were centrifuged
again and resuspended in PBS 5% Donkey serum-0.1%
Triton X-100 with the primary antibody in the
correspondent sample. We left the samples for 30 min at
room temperature. Next, secondary antibody (1:500) was
added and left for 30 min at room temperature. Samples
were washed two times with PBS and analyzed by flow
cytometry.
Immunofluorescence
For immunofluorescence, iPSC, iPSC-AEC2 (day 22),
and endogenous human AEC2 were previously plated in
coverslips. Cells were fixed with 4% paraformaldehyde
for 20 min. For immunofluorescence staining, cells were
washed with PBS and blocked and permeabilized with
PBS 6% Donkey serum, 1% BSA, and 0.5% Triton during
30min at room temperature. Primary antibody used was
mouse monoclonal anti-NKX 2.1 (1:250), anti-SP-C (1:
50), anti-MUC (1:100), and anti- Oct4 (1:60). Samples
were left over night at 4 °C rocking. The next day, cells
were washed three times with PBS. Secondary antibodies
were both prepared at the same dilution 1:200 (anti-
rabbit Alexa488 and anti-mouse Alexa568). Samples
were left during 1 h at 4 °C in the dark. After 1 h, DAPI
was added for nucleus staining and incubated 10 min at
room temperature. Finally, the slides were mounted on
fluoromont and observed by confocal microscopy.
Alkaline phosphatase
For the reaction of alkaline phosphatase, the kit alkaline
phosphatase blue kit (Membrane Substrate Solution-
ThermoFisher Scientific) was used. Firstly, the cells were
washed with PBS and 0.5 ml of paraformaldehyde 4%
was added for 90 s. Then, cells were washed again with
PBS and a mix of 250 μl of component A and 250 μl of
component B was added and incubated for 30 min at
room temperature. Slides were observed under a trans-
mission microscope. AEC2 should be reactive for alka-
line phosphatase activity and appear blue.
Alvarez-Palomo et al. Stem Cell Research & Therapy          (2020) 11:213 Page 3 of 12
Animals
Sprague-Dawley rats, weighting 200–225 g at the begin-
ning of the experiment, were used, in accordance with
the European Community (Directive 86/609/EEC) and
Spanish guidelines for experimental animals, and it was
approved by the institutional committees of animal care
and research of University of Barcelona.
Bleomycin-induced lung fibrosis
Lung fibrosis was induced by intratracheal instillation of
a single dose of BLM (2.5 U/kg) (Sigma, USA) dissolved
in 400 μl of sterile saline under isofluorane anesthesia
[15]. Control animals received the same volume of sa-
line. The animal body weights were recorded every 2
days during the course of the experiment.
iPSC-AEC2 transplantation
At day 21 of differentiation, cells were labeled by incu-
bating them for 20 min in F12 medium with Vybrant™
DiO Cell-Labeling Solution (ThermoFisher). The next
day, the cells were lifted with 0.05% trypsin and were
washed twice with saline solution and resuspended at
4.5 × 106 cells/ml in saline solution the final concentra-
tion for transplantation. After 15 days of intratracheal
BLM, each animal received 3.0 × 106 cells (suspended in
400 μl of sterile saline) by intratracheal administration
under isofluorane anesthesia. Control animals received
the same volume of saline solution. The animals were
sacrificed 21 days after the induction of lung fibrosis
[15]. To avoid immunological rejection, all the trans-
planted animals started, the same day of cell administra-
tion, an immunosuppressive treatment with cyclosporine
(Novartis) (10 mg/kg, orally) daily until the day of the
sacrifice.
Experimental groups
The animals were randomly distributed into four
experimental groups (n = 6 in each group): (1) control—
saline instillation; (2) control + iPSC-AEC2 transplant-
ation (C + iPSC-AEC2)—saline instillation + iPSC-AEC2
transplantation; (3) BLM—BLM instillation; and (4)
BLM + iPSC-AEC2—BLM instillation + iPSC-AEC2
transplantation.
iPSC-AEC2 engraftment
Engrafted cells were assessed in whole lung single cell
preparations. Lung tissue samples were digested with
trypsin (Sigma, USA), chopped into 1–2 mm2 cubes,
treated with 75 U/ml DNase (Sigma, USA) dissolved in
saline, and filtered through nylon meshes ranging from
150 to 30 μm. The resulting cell suspension was centri-
fuged 10min at 500g and then washed twice with PBS
and analyzed by AMNIS Image StreamX flow cytometry.
Moreover, cell engraftment was also evaluated by
fluorescent microscopy. Before cell transplantation, cells
were labeled by the Vybrant™ DiO Cell-Labeling Solution
(ThermoFisher) following the manufacturer’s protocol.
At the end of the experiment, the lungs were collected,
frozen, and embedded in OCT (Jung, Japan). The nuclei
were stained with DAPI.
Fibrosis measurement
Hidroxyproline content
Lung hydroxyproline content was measured as an indi-
cator of collagen deposition, following the method out-
lined by Woessner [26]. Samples were homogenized and
then hydrolyzed in 6M HCl, and the hydrolysate was
then neutralized with 2.5 M NaOH. Hydroxyproline in
the hydrolysate was assessed colorimetrically at 550 nm
with p-dimethylaminobenzaldehyde. The results are
expressed as micrograms of hydroxyproline per lung.
RNA extraction and cDNA synthesis for in vivo work
To preserve the native ratio between DNA and RNA,
Selfie-qPCR analysis was performed using sample lysate
without nucleic acid extraction as previously described
[27]. Briefly, tissue was homogenized in 100ST DNA/
RNA/Protein Solubilization Reagent (#DCQ100ST,
DireCtQuant) 5 μl/mg. The homogenized tissue was in-
cubated at 90 °C for 3 min with 750 rpm agitation, cen-
trifuged at 10,000×g for 10 min, and the supernatant was
used directly to measure mtDNA, 7SDNA, nuclear
DNA, and mtRNA as described [27].
Strand-specific transcription quantification by Selfie-qPCR
Strand-specific analysis of mtDNA transcription was
performed by Selfie-qPCR as previously described,
adapting the method to qPCR [27]. This method enables
separate analysis of transcriptional activity of each one
of the DNA strands without using a reference gene. The
Selfie-qPCR procedure includes three steps: (1) sample
and mtRNA strand-specific primer pre-annealing in du-
plicate aliquots of the same sample, (2) reverse transcrip-
tion with retro-transcriptase enzyme in one duplicate
and no enzyme in the other duplicate, and (3) qPCR
analysis. To anneal the primers to their complementary
transcripts, a reaction mixture containing the sample
and 500 nM primer in 10 μl of double-distilled water
was heated to 70 °C for 1 min, followed by a gradual de-
crease of temperature to 22 °C. Afterwards, we added
4 μl of reaction buffer 5× (EP0751, ThermoFisher), 2 μl
10 mM dNTPs (R0191, ThermoFisher), 0.5 μl Ribolock
RNase inhibitor (EO0381, ThermoFisher), and double-
distilled water to a final volume of 19.5 μl to each dupli-
cate. After mixing both tubes well, we added 0.5 μl of
Maxima H Minus reverse transcriptase (EP0751, Ther-
moFisher) to one of the duplicates and 0.5 μl of enzyme
storage buffer to the second duplicate. Then, both tubes
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were incubated at 60 °C for 30 min to perform the retro-
transcription, followed by 90 °C incubation for 3 min, to
inactivate the reverse transcriptase. Next, 4 μl of each
duplicate was added to a qPCR reaction mixture con-
taining 100 nM of the corresponding primer, 1× Eva-
Green ddPCR Supermix, in a final volume of 20 μl.
qPCR was performed in a thermal cycler (C1000 Touch
Thermal Cycler, Bio-Rad) using the following thermal
profile: 95 °C 5min, (95 °C 30 s; 60 °C 1min) 40 repeats,
4 °C 5min, and 90 °C 10min. Non-template controls
containing all the reagents and the corresponding
amount of solubilization buffer without sample lysate
were included in all steps of the procedure. The number
of mtRNA transcripts was calculated by subtracting the
amount of amplicons measured in the reaction without
reverse transcriptase (RT−) from the reaction with re-
verse transcriptase (RT+) and dividing by (RT−). The
used primers for TGF-β were forward 5′GACTCTC-
CACCTGCAAGACC3′ and reverse 5′GGACTGGC-
GAGCCTTAGTTT3′ and for α-SMA were forward and
reverse forward 5′CATCACCAACTGGGACGACA3′
and reverse 5′TCCGTTAGCAAGGTCGGATG3′.
SDS-PAGE and Western blot
Protein samples were extracted using Nonidet P-40 buf-
fer. SDS-PAGE was performed on 5–13% acrylamide
gels. Proteins were electrotransferred to nitrocellulose
membrane and probed with primary antibodies. The
antibodies used included mouse anti-α-SMA (Acris
Antibodies, Germany), molecular weight 42 kDa, and
mouse anti-β-actin (Sigma, USA), molecular weight 42
kDa, which served as a housekeeping reference. The
membranes were incubated with the corresponding
peroxidase-conjugated secondary antibodies, washed,
and then incubated with ECL reagents (GE Healthcare
Europe GmbH; Freigburg; GE) before exposure to high-
performance chemiluminescence films. Gels were cali-
brated using Bio-Rad standard proteins (Hercules, CA)
with markers covering a 7–240-kDa range.
Films were scanned by using image-editing software
NIH ImageJ software for densitometric analysis of im-
munoreactive bands.
Immunostaining studies
For the immunofluorescence studies, the lungs were col-
lected, frozen, and embedded in OCT (Jung, Japan).
Eight-micrometer tissue sections were obtained, and the
α-SMA protein was assessed using an antibody against
α-SMA (Abcam, UK) and revealed with a secondary
antibody anti-mouse FITC (Acris, Germany). The α-
SMA was observed in green color. The nuclei were
stained with DAPI. Tiling fluorescent microscopy was
used to assess more than 10% of each section and 2000
cells counted for each condition.
Histology
The lungs used for histology were inflated and fixed with
10% neutral buffered formalin, immersed in the fixative
solution for 24 h, and paraffin-embedded. Four-
micrometer sections were stained with hematoxylin-
eosin and Masson’s trichrome to identify inflammatory
cells, connective tissue, and collagen deposition.
Statistical analysis
Data are expressed as mean ± SEM values with 95% con-
fidence intervals (CIs). Statistical analysis was carried
out by analysis of variance (ANOVA) followed by appro-
priate post hoc tests, including the Newman-Keuls test
when differences were significant (GraphPad Software
Inc., USA). A p value of < 0.05 was considered
significant.
Results
Differentiation of human iPSC to AEC2
For the production of iPSC-derived AEC2, we used a
commercially available human iPSC line (cord blood
cells reprogrammed with episomal vectors, Thermo-
Fisher) and applied a previously published differentiation
protocol to AEC2 described by the Kotton group [24]
(Fig. 1a). Cells were adapted to single cell passaging and
differentiated to definitive endoderm using a commercial
kit (Stem Cell Technologies). After 3 days, the cells had
acquired the characteristic polygonal shape of definitive
endoderm and RT-PCR analysis showed enhanced ex-
pression of typical definitive endoderm markers: C-KIT,
CXCR4, and SOX17 (Fig. 1c). Definitive endoderm cells
were then replated and transferred sequentially to anter-
ior foregut endoderm induction medium, lung progeni-
tor induction medium, and finally AEC2 induction
medium. At day 22, the end of the differentiation proto-
col, the cells had changed significantly in morphology
and looked clearly epithelial (Fig. 1b). To check that no
undifferentiated iPSC were left at day 22, we assessed
the expression of the pluripotency marker Oct3/4 and
found reduced gene expression (Fig. 1d) and protein
levels in differentiated cells (Fig. 1e).
Characterization of human iPSC-AEC2
To demonstrate that the differentiated cells had acquired
an AEC2 phenotype, we first stained for alkaline phos-
phatase activity, a well-established general marker for
AEC2, and observed clear foci of alkaline phosphatase-
positive cells (Fig. 2a). Next, we analyzed the capacity of
the cells to express typical AEC2 markers. At the protein
level, we saw that iPSC-AEC2 at day 22 expressed SP-C
in the cytosol and accumulated in granules, with resem-
blance to the pattern observed in endogenous human
AEC2 from donor lung (Fig. 2b). We also stained for
MUC1, an epithelial marker that is mostly found in
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Fig. 1 a Schedule of the differentiation protocol from iPSC to AEC2. b Open field photographs of the iPSC during differentiation, at DE stage (day 3)
and AEC2 stage (day 22). The arrows indicate typical epithelial shape cells. c RT-PCR data for DE markers of cells at day 3. d RT-PCR data for
pluripotency marker OCT4 of cells at day 22. e Immunofluorescence staining for OCT4 (green) in iPSC at day 0 and iPSC-AEC2 at day 22. Nuclei were
stained with DAPI (blue). DE, definitive endoderm; AFE, anterior foregut endoderm; iPSC, induced pluripotent stem cells; AEC2, alveolar type II cells
Fig. 2 a Alkaline phosphatase staining (blue) of iPSC-AEC2 at day 22. The arrows indicate alkaline phosphatase-positive cells. b
Immunofluorescence staining for SP-C (red) in ehAEC2 and in iPSC-AEC2 at day 22, and MUC1 (red) iPSC-AEC2 at day 22. Nuclei were stained
with DAPI (blue). c RT-PCR data for AEC2 cell markers (NKX2.1, DNP63a, FOXA2, FOXA1, GATA6, FOXP2) and AEC1 cell markers (AQ5) of iPSC at
day 0 and day 22 and of ehAEC2 cells. d RT-PCR data for AEC2 markers (SP-C, SP-A) of iPSC at day 0 and iPSC-AEC2 at day 22 and of ehAEC2
cells. iPSC-AEC2, induced pluripotent stem cells derived to alveolar type II cells; AEC2, alveolar type II cell; AEC1, alveolar type I cell; ehAEC2,
endogenous human AEC2; SP-C, surfactant protein C; SP-A, surfactant protein A
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airway cells, and observed sporadic expression indicating
that the population was not totally pure alveolar (Fig. 2b).
Next, we assessed gene expression levels of a battery of
genes typically expressed in AEC2: NKX2.1, P63,
FOXA2, FOXA1, GATA6, FOXP2, SP-C, SP-A, and
AEC1 typical marker AQ5. All samples demonstrated in-
creased gene expression (Fig. 2c). FOXA1 and FOXP2
gene expression levels were found to be comparable to
those of endogenous human lung AEC2. Those marker
indicating more mature alveolar cells, SP-C and SP-A,
were overexpressed to modest levels compared to en-
dogenous AEC2, indicating that iPSC-AEC2 were prob-
ably not fully mature.
Transplantation of human iPSC-AEC2 into the lungs of
bleomycin rat model
BLM instillation of rat lungs initially causes a loss in
body weight that normally recovers, and we observed
that iPSC-AEC2 transplantation did not modify the body
weight with time (Fig. 3a). However, the lung weight
showed a significant decrease in the iPSC-AEC2 trans-
planted group compared with the BLM group, suggest-
ing less fibrosis (Fig. 3b). Therefore, the amount of
hydroxyproline, a modified amino acid specifically found
in collagen, was assessed to determine how iPSC-AEC2
transplantation could alter the natural course of BLM-
induced lung injury. BLM lungs showed a significant in-
crease in the amount of lung hydroxyproline when com-
pared with the control groups (Fig. 3c). In contrast,
levels of hydroxyproline were significantly reduced in
the BLM + iPSC-AEC2 transplanted group which did
not significantly differ from levels observed in the con-
trol groups (Fig. 3c). These results confirm that trans-
plantation of iPSC-AEC2 induces a reduction in collagen
deposition and as a consequent of the fibrotic response.
To further examine the effect of iPSC-AEC2 transplant-
ation in BLM-induced pulmonary fibrosis, serial lung
sections were stained with hematoxylin-eosin or Mas-
son’s trichrome (Fig. 3d–f). To have a whole vision of
lung tissue, Masson’s trichrome-stained lung sections
were examined by stereomicroscopy that illustrates the
heterogeneous topography of the fibrotic lesions (patchy
areas of lung fibrosis) (Fig. 3d). BLM lungs showed ex-
tensive areas of fibrosis compared with BLM + iPSC-
AEC2 transplanted lung that had less fibrosis (Fig. 3d).
Moreover, fibrotic lesions were examined by light mi-
croscopy, and lung tissue sections from control rats
showed no evidence of inflammation or epithelial dam-
age. As expected, lung tissue sections from rats with
BLM-induced fibrosis showed marked peribronchiolar
and interstitial infiltration with inflammatory cells, ex-
tensive cellular thickening of interalveolar septa, intersti-
tial edema, increased interstitial cells with a fibroblastic
appearance, and excessive collagen deposition (Fig. 3e,
f). Although multifocal parenchymal lesions and septal
widening were still present in the lungs transplanted
with iPSC-AEC2, the organized fibroblast foci were
smaller and considerably less frequent than were ob-
served in the BLM lungs. The reduction in parenchymal
lesions is clearly observed with large areas of undamaged
tissue with normal alveolar architecture (Fig. 3e, f).
Compared with the BLM group, BLM + iPSC-AEC2
transplanted animals showed less edema and less colla-
gen deposition. Assessment of cell engraftment of trans-
planted human iPSC-AEC2 in single cell preparations of
the rat lung tissue by AMNIS Image StreamX flow cy-
tometry and by fluorescent microscopy failed to detect
any cell engraftment (Fig. 4), suggesting a paracrine
effect.
Transplanted human iPSC-AEC2 reduce α-SMA-positive
cell fibrosis
To confirm the decrease in fibrosis induced by iPSC-
AEC2 transplantation, we studied the changes in gene
expression of fibrotic markers TGF-β and α-SMA.
Quantitative real-time PCR analysis revealed a signifi-
cant increase in the expression of both markers in the
BLM group, compared to the control group (Fig. 5a, b).
iPSC-AEC2 transplantation in fibrotic animals signifi-
cantly decreased gene expression levels of TGF-β and α-
SMA compared to control levels (Fig. 5a, b). High levels
of α-SMA in BLM animals indicate an increase in the
amount of myofibroblasts that are directly related to fi-
brosis. In this regard, and in order to evaluate one of the
mechanisms involved in the beneficial effect of iPSC-
AEC2 transplantation, we also evaluate the presence of
myofibroblasts and the α-SMA protein release. Results
showed that iPSC-AEC2 transplantation strikingly re-
duced the number of α-SMA-positive cells and the levels
of α-SMA release in the lung tissue of transplanted ani-
mals compared with the fibrotic BLM animals (Fig. 5c,
d). The results indicate that one of the mechanisms in-
volved of the positive effect of transplanted iPS-AEC2 is
related with a significant reduction in α-SMA and TGF-
β gene expression.
Discussion
In the last decade, different cell therapies using various
types of cells have been proposed as prospective novel
IPF treatments. In this study, we evaluated the thera-
peutic effect of iPSC-AEC2 after 15 days of BLM admin-
istration in rats, when fibrosis had already developed in
the animal lungs. We demonstrate that intratracheal
transplantation of AEC2 derived from iPSC is able to de-
creased lung fibrosis. The discovery and development of
new technologies to treat lung disease that includes IPF
are essential because of a limited repertoire of currently
available therapies [1–3].
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The timing for cell transplantation is a critical factor
determining the effect of therapy. The development of
the BLM-induced pulmonary fibrosis model has three
different well-recognized phases. In the first 3 days after
BLM instillation, an acute inflammatory response is trig-
gered; after 7 days, fibroblasts begin to proliferate; after
15 days, the disease is already fully developed [15]. This
last phase is characterized by the loss of lung
Fig. 3 (See legend on next page.)
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architecture due to remodeling process, where there is
an increase in the deposition of ECM components to-
gether with a large proliferation of fibroblasts and α-
SMA-positive cells [15]. Over the last decade, a great
number of preclinical studies based in cell therapies have
been conducted as prospective treatment for IPF. Vari-
ous types of cells have been used, including different
stem cells such as bone marrow-derived mesenchymal
cells, hematopoietic stem cells, adipose stem cells, em-
bryonic stem cells, iPSC, and lung stem cells [13, 28, 29].
Additionally, AEC2 and lung mixed epithelial cells have
also been investigated [13, 28, 29]. Usually, most cell re-
placement therapy strategies have been assayed as a pre-
treatment, after 24 h of BLM administration or during
the early stages of fibrosis development 3 or 7 days after
BLM [13, 28, 29]. In general, cell administration during
these initial stages of the disease showed very promising
results, because many of these cell types are able to in-
hibit the inflammatory response, leading to the
slowdown of fibrogenesis. However, some stem cell ther-
apies demonstrated controversial results related to effi-
cacy when cells were administered during the fibrotic
phase and even shown some aberrant action [28, 29].
This could be explained because stem cells could differ-
entiate into fibroblasts and therefore most likely increase
the development of fibrosis [28, 29]. Nevertheless, the
administration of AEC2 at 3, 7, and 15 days after BLM
administration demonstrated a reduction in fibrosis even
in the fibrotic phase [15, 16]. The use of lung progenitor
cells or differentiated lung cells would explain why this
cell type increases the effectiveness during the fibrotic
phase. Consistent with these latest studies, our results
also demonstrated that iPSC-AEC2 transplantation is
able to significantly reduce collagen deposition when fi-
brosis is already formed. Moreover, the transplanted
iPSC-AEC2 inhibited the expression of TGF-β and α-
SMA in the animal lung tissue. TGF-β is a powerful
pro-fibrotic factor, and its overexpression induces ECM
(See figure on previous page.)
Fig. 3 a Curves of animal body weight over time. On day 0, the animals received bleomycin (BLM). The arrowhead indicates the day of iPSC-
AEC2 cell transplantation (day 14). Data are means ± SEM of 6 animals per group (*p < 0.05 vs control groups). b Lung weight at the end of the
experiment (21 days). iPSC-AEC2 cell transplantation reduced significantly the lung weight compared to the BLM group. Data are means ± SEM of
6 animals per group (*p < 0.05 vs control groups, #p < 0.05 vs BLM group). c Lung hydroxyproline (HP) levels at the end of the experiment (21
days). iPSC-AEC2 cell transplantation reduced significantly the total lung content of hydroxyproline compared with the BLM group. Data are
means ± SEM of 6 animals per group (*p < 0.05 vs control groups, #p < 0.05 vs BLM group). d Representative photographs of lung sections stained
with Masson’s trichrome from all the experimental groups. Insets show changes in the multifocal parenchymal lesions in BLM non-transplanted
lungs and BLM iPSC-AEC2 transplanted lungs. e Representative photomicrographs of lung sections stained with hematoxylin-eosin; iPSC-AEC2
transplantation in fibrotic animals was able to ameliorate the inflammatory and pulmonary lesions (inset). Magnification × 200. f Representative
photomicrographs of lung sections stained with Masson’s trichrome; the presence of interstitial collagen (blue staining, inset) was also diminished
in the BLM + iPSC-AEII group. Magnification × 200
Fig. 4 a Flow cytometry AMNIS Image StreamX analysis of whole lung single cell preparations. Histograms and photo of cells from flow
cytometry by AMNIS Image StreamX analysis of whole lung single cell preparations to detect transplanted cells in rat lungs after 1 week
transplantation. Control and control + iPSC-AEC2 groups where no labeled cells were BLM and BLM + iPSC2 groups demonstrating that no
positive cells (zone R4) could be found 1 week after transplanting in the rat lung. MC_BF, Multi-Channel_Bright Field; MC_CFDA,
Channel_Vybrant™ Cell Fluorescent Dye; MC, Multi-Channel. b Detection of iPSC-AEC2 engraftment after cell transplantation by fluorescence
microscopy. For tracking cell purposes, iPSC-AEC2 cells were labeled with green with Vybrant™ DiO. Nuclei were stained in blue with DAPI. No
green cells were observed in the transplanted groups over background/autofluorescence signal in the rat lungs (control + iPSC-AEC2 and BLM +
iPSC-AEC2). Magnification × 400
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protein synthesis and regulates the differentiation from
fibroblasts to myofibroblasts. At the same time, myofi-
broblast activation requires the presence of ECM pro-
teins and TGF-β. The decreased expression of TGF-β
and α-SMA observed after iPSC-AEC2 transplantation
can in turn diminish fibrosis by decreasing the expres-
sion of collagen, myofibroblast differentiation, and pro-
liferation. This is associated with a decrease in fibrotic
lesions and lung alveolar architecture improvement. As
we stated above, most cell therapies have been con-
ducted during the early stages of fibrosis development,
and therefore, it is difficult to compare our work with
previous studies. To date, few of the reported studies
have been performed with IPSC derived into lung
lineage cells [30–32]. In those studies, iPSC-AEC2 were
administered during the first 24 h or 3 days after BLM
administration and both studies reported a decrease in
inflammation and fibrosis [30–32]. Although these
works agree with our results, it is important to take into
account that they were not performed during the fibrotic
phase of the disease development.
We exhaustively searched for evidence of transplanted
iPSC-AEC2 at the time of sacrifice of the animals by sin-
gle cell flow cytometry and by fluorescent microscopy of
dissected lung tissue. The absence of the implanted cells
1 week after the transplantation suggests that the cells
failed to engraft as a true cell replacement therapy, des-
pite immune suppression treatment of animals. These
results do not correspond as reported by other research
conducted with iPSC-AEC2 or ACE2 where cell engraft-
ment was observed; however, the percentage of
engrafted cells in those studies was not stated [15, 16,
30–32]. Booh and colleagues reported only 1% of cells
engraft after transplantation [31]. In our work, although
Fig. 5 a, b Changes in the mRNA expression of markers for fibroblast activation (TGF-β and α-SMA) were evaluated by Selfie-qPCR. Data are
means ± SEM of 6 animals per group (*p < 0.05 vs control groups, #p < 0.05 vs BLM). c Immunohistological staining with anti-α-SMA (green) shows
the presence of α-SMA-positive fibroblast in BLM animals. iPSC-AEC2 cell transplantation reduces the number of α-SMA-positive cells.
(magnification × 400). d Graph of integrated optical density (area × density) of each band using Image-Pro plus software for α-SMA analyzed by
immunoblot and normalized to β-actin (n = 2 for control, control + iPSC-AEC2, and BLM; n = 3 for iPSC-AEC2). Data are means + SEM (n = 2 for
control, control + iPSC-AEC2, and BLM; n = 3 for iPSC-AEC2)
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engrafted cells were not found in the lungs after 1 week
of transplantation, beneficial effects were observed that
could be due to several aspects: (i) loss of cell dye, (ii)
iPSC-AEC2 were replaced by endogenous progenitor
cells, or (iii) the cells were not engrafted and the positive
effects were due to a paracrine effect. In agreement with
the latter scenario, it has been reported that the adminis-
tration of conditioned medium from iPSC was able to
reduce the levels of inflammatory cytokines, chemokines,
and collagen deposition [33]. This warrants further in-
vestigation in our model whether there is a real engraft-
ment of the cells or if there is a paracrine effect of the
transplanted cells.
Another key challenge in the field of cell replacement
therapy strategy that must be addressed is the possibility
of chromosomal mutations that would lead to the for-
mation of tumors post-cell transplantation into the lung
[34]. In our study, we did not observe any tumors in the
transplanted lungs, albeit at a short time point after cell
transplantation. Accordingly, other studies have also not
found evidence of tumors in the lung, even after 12
months of iPSC-AEC2 transplantation [31].
Although our protocol for cell differentiation from
iPSC into AEC2 has been effective with high efficiency,
it is important to develop further a protocol where the
differentiation will be fully efficient. Our iPSC differenti-
ated into AEC2 did not fully resemble endogenous lung
AEC2 by expression of some specific gene markers, in
particularly SP-C expression levels. Further development
of the protocol and niche mimicking, which might only
be achieved inside the lung architecture, is warranted.
Reaching the full mature phenotype is hard to achieve
because it may demand using lung niche mimicking
strategies such as (i) architecture, (ii) a dynamic fluid
flow, or (iii) transplantation in vivo. Possible modifica-
tions of the protocol to improve the maturation could
potentially use 3D gels or exposing the AEC2 to an air-
liquid interphase in the final part of the differentiation
protocol. For example, the group of Kotton has designed
3D alveolospheres that are found to outperform 2D cul-
tures in AEC2 differentiation and functionality [24].
However, we considered that for the purpose of trans-
plantation, single cells would be better to reach the thin
passages of alveoli. This warrants future work to define
and using 3D lung structures in future studies to develop
advanced iPSC-AEC2 stem cell replacement therapy to
treat lung disease.
There are multiple therapeutic applications of this
work. Our results indicate that iPSC-AEC2 is a promis-
ing new advanced cell therapy because the isolation of
lung stem/progenitor AEC2 from the lung is a compli-
cated process with limited availability. The use of iPSC
differentiated to AEC2 is an easy and efficient approach
for the lung cell-based therapy that allows for autologous
cell transplantation. In addition, the derivation of iPSC
bypasses the ethical concern associated with the use of
human embryonic stem cells and provides an alternative
source of cells that can be used as donor cells for cell
therapy. Alternatively, iPSC banks from HLA homolo-
gous donors could provide HLA-matched lung cells that
would involve minimal immune rejection of the grafted
cells.
In conclusion, this a first study to transplant iPSC-
AEC2 15 days after BLM instillation during the fibrotic
stage of the disease. We confirm that human iPSC-
derived AEC2 can acquire the AEC2 phenotype in vitro.
Intratracheal transplantation of iPSC-AEC2 is able to re-
duce pulmonary fibrosis when fibrosis has already devel-
oped, decreasing the amount of collagen by the
inhibition of both TGF-β and α-SMA expression.
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